EJBY, Denmark , Sept. 9, 2024 /PRNewswire/ -- Today Scantox, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK based GLP compliant genetic toxicology Contract Research Organization ("CRO"). Gentronix, now integrated into Scantox Group, is well recognized for its high-quality genetic toxicology services and strong scientific engagement, with an undisputed track record of serving a loyal and broad global customer base.
With the acquisition of Gentronix, Scantox's service platform expands significantly to meet client demands as a market leading CRO to support pre-IND enabling studies. For 25 years, Gentronix has provided genetic toxicology solutions to the global pharma, biotech and agrichem industries; enabling clients to optimize their development programs by enabling early identification of genotoxic compounds and supporting late-stage development phases with GLP studies. Gentronix offers a comprehensive portfolio of screening and regulatory genotoxicity assays and services, not least the OECD 488 Big Blue® Transgenic Rodent Mutation assay, as one of only three global providers.
Further, Gentronix has expertise and services within ocular and skin toxicology endpoints. Founded in 1999 by Prof. Richard Walmsely , Gentronix is located within the North West UK at the Alderley Park and employs close to 70 employees after a significant scale-up over the past 5 years.
"I am thrilled that Scantox Group has been able to partner up with Gentroni.